Sym015 (Anti-MET) in Patients with Advanced Solid Tumor Malignancies

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 57

Inclusion Criteria

Main inclusion criteria all patients, Part 1 and Part 2:
• Male or female, at least 18 years of age at the time of informed consent
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• Life expectancy > 3 months assessed during Screening
• Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic, and that is refractory to standard therapy or for which no standard therapy is available
• Tumor documented to be KRAS WT by local assessment (i.e. the tumor must express the KRAS WT, exon 2, 3 and 4)

Additional main inclusion criteria applicable to Part 2, Basket Cohort patients ONLY:
• Measurable disease according to RECIST v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) within 4 weeks prior to Cycle 1/Day 1 (C1/D1)
• Confirmed MET-amplification
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 37
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

Main exclusion criteria all patients, Part 1 and Part 2:
• Any antineoplastic agent (standard or investigational) within 4 weeks prior to C1/D1
• Immunosuppressive or systemic hormonal therapy within 2 weeks prior to C1/D1 with specified allowed exceptions
• Use of hematopoietic growth factors within 2 weeks prior to C1/D1
• Active second malignancy or history of another malignancy within the last 3 years, with specified allowed exceptions
• Central nervous system (CNS) malignancy including primary malignancies of the CNS, known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required
• Inadequate recovery from an acute toxicity associated with any prior antineoplastic therapy
• Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any prior surgical procedure
• Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 1 month prior to C1/D1, unless adequately treated and stable
• Active uncontrolled bleeding or a known bleeding diathesis
• Significant cardiovascular disease or condition
• Abnormal hematologic, renal or hepatic function
• Any of the following within 2 weeks prior to C1/D1:
o Any serious or uncontrolled infection
o Any infection requiring parenteral antibiotics
o Unexplained fever > 38.0 °C

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials